Synthesis of epothilones, intermediates thereto and analogues thereof

• US 7,759,374 B2
• Filed: 10/12/2006
• Issued: 07/20/2010
• Est. Priority Date: 08/23/2002
• Status: Expired due to Fees

• Current Assignee: Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Original Assignee: Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Inventors: Gabarda, Ana E., Dong, Huajin, Yoshimura, Fumikiko, Danishefsky, Samuel J., Chou, Ting-Chao, Rivkin, Alexey
• Primary Examiner(s): Saeed; Kamal A
• Assistant Examiner(s): BIANCHI, KRISTIN A
• Application Number:
  US11/546,715
• Publication Number:
  US 20070032534A1
• Time in Patent Office: 1,377 Days
• Field of Search: 514/365, 514/183, 514/450, 514/374, 514/378, 548/181, 548/202, 548/203, 548/235, 548/247, 540/451, 540/455
• US Class Current: 514/365
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 313/00 Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
• CPC Class Codes: C07D 413/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 417/02 containing two hetero rings
• CPC Class Codes: C07D 417/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 493/04 Ortho-condensed systems

Abstract

The present invention provides compounds of formula (I):

• • as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provides methods of treating cancer comprising administering a compound of formula (I).

Claims

1. A compound having the formula:

2. The compound of claim 1 wherein R₂ is a substituted or unsubstituted heteroaryl moiety.

3. The compound of claim 2, wherein the heteroaryl moiety is substituted or unsubstituted isoxazolyl.

4. The compound of claim 3, wherein R₅ and R₆ are each hydrogen.

5. The compound according to claim 3 or 4 wherein the heteroaryl moiety is substituted isoxazolyl.

6. The compound according to claim 3 or 4 wherein the heteroaryl moiety is unsubstituted isoxazolyl.

7. The compound according to claim 5 wherein the isoxazolyl group is substituted with an aliphatic moiety.

8. The compound according to claim 7 wherein the isoxazolyl group is substituted with a C_1-4 alkyl group.

9. The compound according to claim 8 wherein the isoxazolyl group is substituted with a methyl group.

10. A pharmaceutical composition comprising a compound according to any one of claims 1, 2, 3, or 4-9, or a pharmaceutically acceptable salt thereof;

and a pharmaceutically acceptable carrier or diluent.